Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical SOR007 for Cutaneous Metastases
NCT03101358Phase 2Completed
- Sponsor
- NanOlogy
- Start
- Jan 2018
- Primary completion
- Apr 2020
- Countries
- 1
01
Overview
Phase 2, open-label trial of SOR007 Ointment Placebo in cutaneous metastasis (CM) (3 arms), sponsored by NanOlogy. Primary endpoint: Incidence of Treatment Emergent Adverse Events at Day 86. Started Jan 2018; status: completed.
02
Drugs
SOR007 Ointment Placebo
03
Conditions
cutaneous metastasis (CM)
Beyond the preview
Go deeper on NCT03101358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03101358.